Lv Xingxing, Gou Fusheng, Shen Yuan, Lu Hong, Chen Juan, Liu Juan, Chen Hui, Zhang Xuan, Yu Danfei
Department of Oncology and Hematology, People's Hospital of Leshan.
Department of Critical Care Medicine, People's Hospital of Leshan, Leshan, Sichuan, PR China.
Medicine (Baltimore). 2018 Nov;97(48):e13464. doi: 10.1097/MD.0000000000013464.
Advanced non-small-cell lung cancer (NSCLC) is an aggressive malignancy that generally leads to poor outcomes, with <5% long-term survival at 5 years; however, several researches have shown improvements in the progression-free survival (PFS) and overall survival (OS) on the maintenance therapy after the first-line chemotherapy. we report a case of metastatic NSCLC patient treated with maintenance therapy of gemcitabine with brilliant results.
Clinical data and treatment of a 68-year-old man with NSCLC are summarized. The Ethics Committee of People's hospital of Leshan, approved this study.
Lung adenocarcinoma metastasized to the mediastinal lymph node, cervical lymph node, and adrenal gland, without epidermal growth factor receptor (EGFR) mutation.
Continued treatment with gemcitabine alone following the 6 cycles of cisplatin-gemcitabine chemotherapy, prolonging the interval of chemotherapy when he could not tolerate the toxicity of the drug.
Partial response of the disease for 4.5 years and significant clinical benefit.
This case shows that patients will benefit from the maintenance therapy, and gemcitabine may be a good choice.
晚期非小细胞肺癌（NSCLC）是一种侵袭性恶性肿瘤，通常预后较差，5年长期生存率<5%；然而，多项研究表明一线化疗后的维持治疗可改善无进展生存期（PFS）和总生存期（OS）。我们报告1例接受吉西他滨维持治疗的转移性NSCLC患者，结果良好。
总结1例68岁NSCLC男性患者的临床资料及治疗情况。乐山人民医院伦理委员会批准了本研究。
肺腺癌转移至纵隔淋巴结、颈部淋巴结及肾上腺，无表皮生长因子受体（EGFR）突变。
在顺铂-吉西他滨化疗6个周期后继续单用吉西他滨治疗，在患者无法耐受药物毒性时延长化疗间隔时间。
疾病部分缓解4.5年，临床获益显著。
该病例表明患者将从维持治疗中获益，吉西他滨可能是一个不错的选择。
